NewsFeeder
Headline News
- Reaction score
- 4
Gilead’s Remdesivir Supply Will Fall Short of U.S. Need This Summer, Analyst Says
The number of doses of the Gilead Sciences Covid-19 antiviral remdesivir being allocated to the U.S. is smaller than expected, according to analyst Brian Abrahams at RBC Capital Markets.
https://finance.yahoo.com/m/9d41162...00b/gilead’s-remdesivir-supply.html?.tsrc=rss
The number of doses of the Gilead Sciences Covid-19 antiviral remdesivir being allocated to the U.S. is smaller than expected, according to analyst Brian Abrahams at RBC Capital Markets.
https://finance.yahoo.com/m/9d41162...00b/gilead’s-remdesivir-supply.html?.tsrc=rss
